A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 6, 2018

Primary Completion Date

December 10, 2019

Study Completion Date

January 10, 2020

Conditions

B-cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

CD19-directed CAR-T cells

CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

collaborator

Shanghai AbelZeta Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER

NCT03483688 - A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects | Biotech Hunter | Biotech Hunter